Trending: Novartis Shares Climb on Guidance Lift
1240 GMT - Novartis is among the most mentioned companies across news items over the past 12 hours, according to Factiva data. The Swiss pharma giant's shares surged after it lifted its full-year guidance on profit and sales that rose in the first quarter. The stock traded 5.4% higher at CHF92.03 earlier, making it one of today's best performers in the Stoxx 600 index. Shares of Novartis grew 7.2% year-to-date. In addition to Novartis's first-quarter results beating expectations, the company also confirmed it isn't experiencing any drug shortages following its strategic refocus on specialty medicines in its four core therapeutic areas, which it undertook last year, Chief Financial Officer Harry Kirsch said in a press call. Dow Jones & Co. owns Factiva. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 23, 2024 08:55 ET (12:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How the Tokyo Stock Exchange Is Pushing for Better Capital Allocation
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting